Spots Global Cancer Trial Database for Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Official Title: Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma
Study ID: NCT02297958
Conditions
Interventions
Study Description
Brief Summary: Ovarian carcinoma has poor prognosis and new therapeutic strategies are required. Many patients with ovarian carcinoma showed resistance to chemotherapy. Cleaved FasL is known for induced atypical response when is binding to Fas such as avoiding apoptosis and inducing cell motility.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Service de Gynécologie, Rennes, , France
Contact Details
Name: Vincent Lavoue, PH
Affiliation: Rennes University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
